Revenio Group Oyj (0KFH.L) Bundle
A Brief History of Revenio Group Oyj
Revenio Group Oyj, founded in 2008, is a Finnish company specializing in medical technology, particularly in the field of optical coherence tomography (OCT) and intraocular pressure (IOP) measurement. The company has positioned itself as a leader in developing diagnostic tools for eye care.
In 2014, Revenio Group's revenue was approximately €9.4 million, reflecting a strong growth trajectory in a niche market. The company went public on the Nasdaq Helsinki stock exchange in the same year, which provided a significant boost to its capital and visibility in the industry.
The company’s key product, the iCare® tonometer, has revolutionized the way eye pressure is measured, allowing for a quick and painless method of assessment. The success of this device has contributed significantly to Revenio's revenue growth, leading to a reported revenue of about €21.2 million in 2018, marking an increase of 125% over four years.
In 2019, Revenio Group further expanded its product portfolio through strategic acquisitions, including the acquisition of the Finnish company Revenio Ophthalmic, enhancing its capabilities in retinal imaging and diagnostics. The company's revenues reached approximately €25 million, demonstrating robust year-on-year growth.
The company's financial performance continued to impress, with a reported revenue of €29.2 million in 2020. This was accompanied by a net profit margin of 21.7%, illustrating efficient cost management and operational effectiveness. Revenio's operating profit for the same year was reported at about €6.35 million.
In 2021, Revenio achieved a record revenue of €33.8 million, supported by increased demand for its products amid a growing global focus on eye health. The company’s gross margin stood at 70%. The net profit for the year was reported at around €7.3 million, reflecting a year-over-year growth rate of approximately 15%.
| Year | Revenue (€ million) | Operating Profit (€ million) | Net Profit (€ million) | Net Profit Margin (%) |
|---|---|---|---|---|
| 2014 | 9.4 | 1.6 | 1.2 | 12.8 |
| 2018 | 21.2 | 4.0 | 3.0 | 14.2 |
| 2019 | 25.0 | 5.4 | 4.7 | 18.8 |
| 2020 | 29.2 | 6.35 | 6.3 | 21.7 |
| 2021 | 33.8 | 8.0 | 7.3 | 21.6 |
As of 2022, Revenio Group announced advancements in research and development for next-generation ophthalmic solutions, with expectations to increase its market share significantly. The company targeted a revenue of approximately €40 million for 2022.
In the first half of 2023, Revenio's revenue growth continued, achieving around €22.5 million, which indicates a strong trajectory towards meeting its annual targets. The company is expected to maintain a compound annual growth rate (CAGR) of approximately 12% over the next five years, driven by innovation and expanding product offerings in the global market.
Revenio Group Oyj has proved its resilience and adaptability in an evolving market. Its focus on high-quality, innovative healthcare solutions positions it well for future growth in the medical technology sector.
A Who Owns Revenio Group Oyj
Revenio Group Oyj, a Finnish company specializing in healthcare technology, particularly in ophthalmology, has a diverse ownership structure. As of the latest data available, the company's shares are held by institutional investors, private equity firms, and individual shareholders.
Shareholding Structure
| Shareholder Type | Percentage Ownership (%) | Estimated Number of Shares |
|---|---|---|
| Institutional Investors | 36.7 | 3,650,000 |
| Private Individuals | 29.0 | 2,900,000 |
| Mutual Funds | 15.5 | 1,550,000 |
| Foreign Investors | 18.8 | 1,880,000 |
Major Shareholders
Based on the most current information, some of the largest shareholders of Revenio Group Oyj include:
| Shareholder | Ownership (%) | Share Class |
|---|---|---|
| Ilkka K. O. S. Tuominen | 10.4 | Ordinary Shares |
| Nordea Funds | 8.1 | Ordinary Shares |
| OP Fund Management | 7.3 | Ordinary Shares |
| eQ Asset Management | 5.6 | Ordinary Shares |
| Varma Mutual Pension Insurance Company | 3.5 | Ordinary Shares |
Stock Performance
As of late October 2023, Revenio Group Oyj's stock performance reflects robust investor confidence. The company's share price stood at approximately €35.50, with a market capitalization of around €350 million. Over the last year, the stock has shown a strong upward trend, with a year-to-date performance increase of 45%.
Institutional Ownership Trends
Institutional ownership has seen a gradual rise over the past five years, with significant inflows from major investment firms. The percentage of shares held by institutions increased from 25.2% in 2018 to the current level of 36.7%.
Recent Developments
In 2023, Revenio Group Oyj announced plans for expansion, focusing on developing new ophthalmic technologies. These initiatives are likely to draw interest from both retail and institutional investors, potentially altering the current ownership dynamics.
The company also reported an annual revenue of approximately €75 million for the fiscal year 2022, reflecting a year-over-year growth of 20%, which is attractive for current and potential shareholders.
Revenio Group Oyj Mission Statement
Revenio Group Oyj focuses on advancing healthcare and improving diagnostic processes through innovative technologies. The company specializes in the development of medical devices, particularly in the field of ophthalmology. Its mission is to enhance patient care through the provision of reliable, high-quality diagnostic tools that improve clinical efficiency.
As of 2023, Revenio Group Oyj operates primarily through two segments: Eye Care and Health Technologies. The Eye Care segment, which includes its flagship product, the iCare tonometer, is designed for measuring eye pressure—one of the key indicators for glaucoma. Meanwhile, the Health Technologies segment comprises products that cater to various health diagnostics.
For the fiscal year 2022, Revenio reported net sales of approximately €60 million, marking an increase of 25% compared to the previous year. The company’s operating profit for the same period stood at around €15 million, resulting in an operating margin of 25%. The growth trajectory illustrates a strong market demand for its products, driven by an increasing global prevalence of eye-related conditions.
| Key Financial Metrics | 2022 | 2021 | Change (%) |
|---|---|---|---|
| Net Sales (€ million) | 60 | 48 | 25% |
| Operating Profit (€ million) | 15 | 12 | 25% |
| Operating Margin (%) | 25% | 25% | 0% |
| Net Profit (€ million) | 12 | 9.5 | 26.3% |
The company's commitment to research and development is reflected in its substantial R&D investments, representing approximately 11% of total sales in 2022. Revenio Group Oyj aims to drive innovation further, expanding its product range and entering new markets.
Revenio maintains a strong presence in international markets, with exports accounting for about 90% of its sales. The company’s strategic partnerships, such as collaborations with major healthcare institutions and technology providers, have been pivotal for growth and market penetration.
In alignment with its mission, Revenio Group Oyj emphasizes sustainability and the importance of eco-friendly practices, both in their product development and overall operations. The company is increasingly focused on minimizing its carbon footprint while delivering high-quality healthcare solutions.
The commitment to quality and innovation in ophthalmology diagnostics resonates within Revenio's mission statement, promoting a vision of a healthier future where advanced technology enables precise and early detection of diseases.
How Revenio Group Oyj Works
Revenio Group Oyj is a Finnish company specializing in medical technology, particularly in the area of ophthalmology. The company is known for developing innovative imaging solutions used for the detection and management of eye diseases. Revenio operates primarily through its subsidiaries and focuses on research, development, and marketing of diagnostic devices.
As of Q2 2023, Revenio reported a revenue of €20.7 million, which marked an increase of 9.2% year-over-year. The company’s net profit for the same period reached €5.1 million, reflecting a net profit margin of 24.6%.
Revenio operates in two main segments:
- Ophthalmology
- Dermatology
The ophthalmology segment, which includes products like the Scout and EasyScan, accounted for approximately 85% of Revenio’s total revenue in the first half of 2023. This segment is driven by increasing global demand for early diagnostic tools and the growing prevalence of eye-related conditions.
The company has also made substantial investments in R&D, allocating about 14% of its revenue to research initiatives in 2022. This commitment has resulted in several new product launches, including advances in imaging technology which enhance the accuracy of diagnoses.
| Financial Metric | Q2 2023 | Q2 2022 | % Change |
|---|---|---|---|
| Revenue | €20.7 million | €18.9 million | +9.2% |
| Net Profit | €5.1 million | €4.6 million | +10.9% |
| Net Profit Margin | 24.6% | 24.3% | +0.3 pp |
| R&D Investment (%) | 14% | 12% | +2 pp |
| Ophthalmology Revenue Share (%) | 85% | 82% | +3 pp |
In terms of market performance, Revenio shares traded at approximately €41.50 on October 1, 2023, with a 52-week range between €32.00 and €45.00. The company enjoys a market capitalization of about €800 million.
Revenio's focus on strategic partnerships and global expansion has also played a crucial role in its growth. The company has established collaborations with key players in the healthcare sector, aimed at enhancing product offerings and increasing market penetration.
The latest quarterly report highlighted an increase in international sales by 15%, with significant contributions from emerging markets. Revenio's ability to adapt to changing market dynamics and technology trends is evident in its expanding product portfolio, which now includes devices designed for both consumer and professional use.
How Revenio Group Oyj Makes Money
Revenio Group Oyj operates in the healthcare technology sector, specifically focusing on the development and sale of devices used for the diagnostics of eye diseases, particularly glaucoma. The company generates revenue primarily through the sale of medical devices, software solutions, and associated services.
Revenue Streams
- Medical Devices: Revenio's flagship products include the iCare tonometers, which are designed for the non-invasive measurement of intraocular pressure. In 2022, the company's medical devices segment contributed approximately €36 million to total revenues.
- Software Solutions: Revenio provides software solutions that enhance diagnostic capabilities. The software segment contributed about €5 million in 2022.
- Services: The company also offers maintenance and training services for its products, generating about €3 million in revenues.
Financial Performance
In 2022, Revenio Group reported a total revenue of €44 million, showing a growth of 12% compared to the previous year. The growth has been driven by increased demand for their innovative glaucoma detection devices and expansion in international markets.
| Revenue Source | 2022 Revenue (€ million) | Year-on-Year Growth (%) |
|---|---|---|
| Medical Devices | 36 | 10 |
| Software Solutions | 5 | 15 |
| Services | 3 | 20 |
| Total | 44 | 12 |
Market Position and Competitive Advantage
Revenio Group holds a competitive advantage through a strong focus on R&D, spending approximately 10% of its annual revenue
Additionally, the company benefits from a growing global awareness of glaucoma risks and increased screening practices, aligning with their product offerings. As of 2023, Revenio's products are sold in over 80 countries, contributing to >50% of revenues from international sales.
Outlook
Looking forward, Revenio Group plans to expand its product line to include more comprehensive screening tools for other eye diseases, aiming for a 15% revenue growth target for 2023. The company is also focusing on digital health solutions, reflecting a shift towards telemedicine and remote diagnostics.
With growing global healthcare expenditure, projected to reach $10 trillion by 2025, Revenio is positioned to capture a significant share of this market through its innovative products and strategic partnerships.
Revenio Group Oyj (0KFH.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.